Trump’s Tariff Blitz Puts UK Drugs, Trucks, and Cabinets in Crosshairs

Donald Trump has unleashed a new wave of trade threats, proposing severe tariffs on a range of goods that has left the UK pharmaceutical industry particularly vulnerable. A potential 100% duty on branded drugs is set to take effect on October 1st, alongside 25% levies on heavy-duty trucks and 50% on kitchen and bathroom cabinets. This move highlights the precarious position of UK drugmakers, who were not included in Keir Starmer’s earlier tariff agreement with the US.
The British government has expressed its concern and is scrambling to engage in dialogue with Washington. A spokesperson stated they would “continue to press the US for outcomes that deliver real benefits for UK industry,” acknowledging the vital importance of the pharmaceutical sector. This diplomatic rush comes despite a recent state visit intended to strengthen ties, which ultimately failed to secure protection for this key industry.
The situation underscores the incomplete nature of the existing UK-US tariff deal, which focused primarily on cars, steel, and aerospace components. While that agreement provided relief for some sectors, it left others, like pharmaceuticals, exposed. Trump had previously promised the UK “preferential treatment” on drug tariffs, a pledge that now appears to have been forgotten amid this latest protectionist push.
Market analysts offer a glimmer of hope, suggesting the tariffs may be a strategic move to encourage manufacturing on US soil. Lale Akoner, a global market analyst, pointed out that major pharmaceutical firms with US plants are likely to be spared. “Investors see more bark than bite,” she commented, citing European giants like Roche and Novartis who are already investing in American facilities and do not expect to be affected.
The ripple effects are being felt across Europe. Germany’s auto industry has condemned the truck tariffs as nonsensical, warning of damage to supply chains and US jobs. Major European truck makers saw their stock prices dip in response to the news. Furthermore, concerns are growing over potential future tariffs on medical devices, an industry where the EU is a major exporter to the US.